Refine by
Prostate Cancer Biopsies Articles & Analysis
13 articles found
The literature shows that pathologists, being only humans under considerable pressure, may miss cancer in up to 1-3% of prostate biopsies.2,3,4 Considering the over one million men who are diagnosed worldwide per year, this may reflect a large number of patients.5 Moreover, the subjectivity of Gleason grading and tumor quantification can result ...
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized by the AI as “suspicious” or as out of distribution were manually reviewed by Yale ...
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer. ...
The ClarityDX Prostate® test is intended to be used as a reflex test for men with elevated levels of PSA, the current prostate cancer screening test, and is designed to help physicians and patients make a more informed decision to proceed with biopsy or not. ...
Organizations Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, MDxHealth, B.V., Nijmegen, Netherlands, MDxHealth, Inc., Irvine, CA, Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium, Martini-Klinik Prostate Cancer ...
Compared to transrectal, transperineal is proven to be the cleaner and ultimately safer approach for prostate biopsies. The support for transperineal is growing, as mounting evidence continues to debunk previous misconceptions of tolerability, feasibility and accuracy. ...
The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution ("Partner"). ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. ...
In addition to being a great stand-alone product and a unique ultrasound solution, clinical studies have reported a diagnostic accuracy similar to MRI in identifying prostate cancer. Further, a recently published study observed an improvement in diagnostic accuracy when ExactVu micro-ultrasound was added to MRI. ...
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ...
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer ...
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: ...
Materials and methods: We developed a Markov decision analytical model to simulate the chain of events and downstream outcomes associated with ultrasound guided prostate biopsy and a strategy in which the biomarker panel is implemented prior to biopsy. ...
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. ...